{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:14:41Z","timestamp":1787786081821,"version":"build-2784847793"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"17","license":[{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4,25]]},"abstract":"<jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>Conducting neoadjuvant chemoradiotherapy (CRT) and additional preoperative consolidating chemotherapy (CTx), that is, total neoadjuvant therapy (TNT), improves local control and complete response (CR) rates in locally advanced rectal cancer (LARC), putting the focus on organ preservation concepts. Therefore, assessing response before surgery is crucial. Some LARC patients would either not benefit from intensification by TNT or may reach CR, making resection not mandatory. Treatment of LARC should therefore be based on patient individual risk and response to avoid overtreatment.<\/jats:p>\n            <jats:p>The \u201cPRIMO\u201d pilot study aims to determine early response assessment to form a basis for development and validation of a noninvasive response prediction model by a subsequent prospective multicenter trial, which is highly needed for individual, response-driven therapy adaptions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>PRIMO is a prospective observational cohort study including adult patients with LARC receiving neoadjuvant CRT. At least 4 multiparametric magnetic resonance imaging (MRI) scans (diffusion-weighted imaging [DWI] and hypoxia-sensitive sequences) as well as repeated blood samples in order to analyze circulating tumor cells (CTC) and cell-free tumor DNA (ctDNA) are scheduled. Pelvic radiotherapy (RT, 50.4 Gy) will be performed in combination with a 5-fluorouracil\/oxaliplatin regimen in all patients (planned: N = 50), succeeded by consolidation CTx (FOLFOX4) if feasible. Additional (immuno)histochemical markers, such as tumor-infiltrating lymphocytes (TIL) and programmed death ligand 1 (PD-L1) status will be analyzed before and after CRT. Routine resection is scheduled subsequently, nonoperative management is offered alternatively in case of clinical CR (cCR).The primary endpoint is pathological response; secondary endpoints comprise longitudinal changes in MRI as well as in CTCs and TIL. These are evaluated for early response prediction during neoadjuvant therapy, in order to develop a noninvasive response prediction model for subsequent analyses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion:<\/jats:title>\n            <jats:p>Early response assessment is the key in differentiating \u201cgood\u201d and \u201cbad\u201d responders during neoadjuvant CRT, allowing adaption of subsequent therapies (additional consolidating CTx, organ preservation). This study will contribute in this regard, by advancing MR imaging and substantiating new surrogate markers. Adaptive treatment strategies might build on these results in further studies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000033575","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T14:06:31Z","timestamp":1682690791000},"page":"e33575","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Planning adaptive treatment by longitudinal response assessment implementing MR imaging, liquid biopsy and analysis of microenvironment during neoadjuvant treatment of rectal cancer (PRIMO)"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8751-9862","authenticated-orcid":false,"given":"Georg W.","family":"Wurschi","sequence":"first","affiliation":[{"name":"Department of Radiotherapy and Radiation Oncology, Jena University Hospital, Friedrich-Schiller University Jena, Jena, Germany"},{"name":"Clinician Scientist Program, Interdisciplinary Center for Clinical Research (IZKF), Jena University Hospital, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"G\u00fcllmar","sequence":"additional","affiliation":[{"name":"Medical Physics Group, Institute of Diagnostic and Interventional Radiology (IDIR), Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Ga\u00dfler","sequence":"additional","affiliation":[{"name":"Section of Pathology, Institute of Forensic Medicine, Jena University Hospital, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Clement","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Jena University Hospital, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Kesselmeier","sequence":"additional","affiliation":[{"name":"Institute of Medical Statistics, Computer and Data Sciences (IMSID), Jena University Hospital, Friedrich-Schiller University Jena, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia J.","family":"M\u00fcller-Wurschi","sequence":"additional","affiliation":[{"name":"Center for Clinical Studies, Jena University Hospital, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utz","family":"Settmacher","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Vascular Surgery, Jena University Hospital, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Mothes","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Vascular Surgery, Sophien- und Hufeland-Klinikum Weimar, Weimar, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herry","family":"Helfritzsch","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Thoracic Surgery, Thuringia-Clinic Saalfeld Georgius Agricola, Saalfeld, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Liebe","sequence":"additional","affiliation":[{"name":"Department of General and Visceral Surgery, SRH Klinikum Burgenlandkreis Naumburg, Naumburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Franiel","sequence":"additional","affiliation":[{"name":"Institute of Diagnostic and Interventional Radiology (IDIR), Jena University Hospital, Friedrich-Schiller University Jena, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias A.","family":"M\u00e4urer","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Radiation Oncology, Jena University Hospital, Friedrich-Schiller University Jena, Jena, Germany"},{"name":"Clinician Scientist Program, Interdisciplinary Center for Clinical Research (IZKF), Jena University Hospital, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ernst","sequence":"additional","affiliation":[{"name":"University Tumor Center (UTC), Jena University Hospital, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils H.","family":"Nicolay","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Leipzig Medical Center, Leipzig, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Wittig","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Radiation Oncology, Jena University Hospital, Friedrich-Schiller University Jena, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S1470-2045(15)00159-X","article-title":"Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO\/ARO\/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.","volume":"16","author":"R\u00f6del","year":"2015","journal-title":"Lancet Oncol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/01.sla.0000141194.27992.32","article-title":"Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.","volume":"240","author":"Habr-Gama","year":"2004","journal-title":"Ann Surg"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1200\/JCO.19.00308","article-title":"Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO\/ARO\/AIO-12.","volume":"37","author":"Fokas","year":"2019","journal-title":"J Clin Oncol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.","volume":"22","author":"Conroy","year":"2021","journal-title":"Lancet Oncol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.22.00032","article-title":"Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy.","volume":"40","author":"Garcia-Aguilar","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"R8-20250504","first-page":"8","article-title":"Totale Neoadjuvante Therapie als Organerhaltende Therapie des Rektumkarzinoms: Die CAO\/ ARO\/ AIO-16 Phase II Studie.","volume":"198","author":"Gani","year":"2022","journal-title":"Strahlenther Onkol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1200\/JCO.20.02199","article-title":"Playing with dynamite? A cautious assessment of TNT.","volume":"39","author":"Shi","year":"2021","journal-title":"J Clin Oncol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"W205","DOI":"10.2214\/AJR.17.19135","article-title":"MRI-based apparent diffusion coefficient for predicting pathologic response of rectal cancer after neoadjuvant therapy: systematic review and meta-analysis.","volume":"211","author":"Amodeo","year":"2018","journal-title":"Am J Roentgenol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1200\/JCO.2010.33.1595","article-title":"Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials.","volume":"29","author":"Valentini","year":"2011","journal-title":"J Clin Oncol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11888-015-0285-2","article-title":"Neoadjuvant Rectal (NAR) score: a new surrogate endpoint in rectal cancer clinical trials.","volume":"11","author":"George","year":"2015","journal-title":"Curr Colorectal Cancer Rep"},{"issue":"15_suppl","key":"R13-20250504","doi-asserted-by":"crossref","first-page":"3843533","DOI":"10.1200\/jco.2014.32.15_suppl.3533","article-title":"Neoadjuvant rectal cancer (RC) score to predict survival: potential surrogate endpoint for early phase trials.","volume":"32","author":"Yothers","year":"2014","journal-title":"J Clin Oncol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"20180642","DOI":"10.1259\/bjr.20180642","article-title":"Imaging tumour hypoxia with oxygen-enhanced MRI and BOLD MRI.","volume":"92","author":"O\u2019Connor","year":"2019","journal-title":"Br J Radiol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"20180655","DOI":"10.1259\/bjr.20180655","article-title":"Diffusion-weighted imaging in rectal cancer: current applications and future perspectives.","volume":"92","author":"Schurink","year":"2019","journal-title":"Br J Radiol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.radonc.2014.11.026","article-title":"The role of diffusion-weighted MRI and 18F-FDG PET\/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: a systematic review.","volume":"113","author":"Joye","year":"2014","journal-title":"Radiother Oncol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13014-020-01613-4","article-title":"Exploring MR regression patterns in rectal cancer during neoadjuvant radiochemotherapy with daily T2- and diffusion-weighted MRI.","volume":"15","author":"Bostel","year":"2020","journal-title":"Radiat Oncol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1158\/1078-0432.CCR-16-1209","article-title":"Noninvasive imaging of cycling hypoxia in head and neck cancer using intrinsic susceptibility MRI.","volume":"23","author":"Panek","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13014-018-1103-1","article-title":"Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET.","volume":"13","author":"Wiedenmann","year":"2018","journal-title":"Radiat Oncol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1007\/s00259-021-05602-x","article-title":"Interleukin-6 as surrogate marker for imaging-based hypoxia dynamics in patients with head-and-neck cancers undergoing definitive chemoradiation-results from a prospective pilot trial.","volume":"49","author":"R\u00fchle","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1007\/s00292-018-0530-y","article-title":"Standardisierte Bestimmung tumorinfiltrierender Lymphozyten beim Mammakarzinom.","volume":"39","author":"Denkert","year":"2018","journal-title":"Der Pathologe"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/DCR.0000000000001332","article-title":"Prognostic impact of tumor-infiltrating lymphocytes in primary and metastatic colorectal cancer: a systematic review and meta-analysis.","volume":"62","author":"Kong","year":"2019","journal-title":"Dis Colon Rectum"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11888-016-0320-y","article-title":"Circulating tumor cells versus circulating tumor DNA in colorectal cancer: pros and cons.","volume":"12","author":"Tan","year":"2016","journal-title":"Curr Colorectal Cancer Rep"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.currproblcancer.2017.11.002","article-title":"The significant prognostic value of circulating tumor cells in colorectal cancer: a systematic review and meta-analysis.","volume":"42","author":"Tan","year":"2018","journal-title":"Curr Probl Cancer"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"9645","DOI":"10.1007\/s11033-020-05973-8","article-title":"The role of circulating tumor cells and K-ras mutations in patients with locally advanced rectal cancer: a prospective study.","volume":"47","author":"Bahnassy","year":"2020","journal-title":"Mol Biol Rep"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"e7586","DOI":"10.1136\/bmj.e7586","article-title":"SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials.","volume":"346","author":"Chan","year":"2013","journal-title":"BMJ"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"2010 Statement: updated guidelines for reporting parallel group randomised trials.","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/cncr.11660","article-title":"Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy.","volume":"98","author":"Becker","year":"2003","journal-title":"Cancer"},{"issue":"15_suppl","key":"R32-20250504","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1200\/jco.2014.32.15_suppl.3532","article-title":"External validation of the neoadjuvant rectal (NAR) score and Valentini prediction nomogram (VPN): a multicenter study.","volume":"32","author":"Raissouni","year":"2014","journal-title":"J Clin Oncol"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/j.ejca.2009.08.014","article-title":"Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life in patients with colorectal cancer.","volume":"45","author":"Whistance","year":"2009","journal-title":"Eur J Cancer"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners.","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033575","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:01:13Z","timestamp":1746324073000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":33,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000033575","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,25]]}}}